Search

Your search keyword '"Pozueta Ana"' showing total 33 results
Start Over Author "Pozueta Ana" Search Limiters Full Text
33 results on '"Pozueta Ana"'

1. Genetic variation in the tau protein phosphatase-2A pathway is not associated with Alzheimer's disease risk

Author

Berciano José, Valdivieso Fernando, Frank-García Ana, Dobato José L, Calero Miguel, Pozueta Ana, Rodríguez-Rodríguez Eloy, Sánchez-Juan Pascual, Mateo Ignacio, Vázquez-Higuera José L, Bullido Maria J, and Combarros Onofre

Subjects
Medicine, Biology (General), QH301-705.5, Science (General), Q1-390
Abstract

Abstract Background Tau abnormal hyperphosphorylation and the formation of neurofibrillary tangles in AD brain is the result of upregulation of tau kinases and downregulation of tau phosphatases. Methods In a group of 729 Spanish late-onset Alzheimer's disease (AD) patients and 670 healthy controls, we examined variations into a set of candidate genes (PPP2CA, PPP2R2A, ANP32A, LCMT1, PPME1 and PIN1) in the tau protein phosphatase-2A (PP2A) pathway, to address hypotheses of genetic variation that might influence AD risk. Results There were no differences in the genotypic, allelic or haplotypic distributions between cases and controls in the overall analysis or after stratification by age, gender or APOE ε4 allele. Conclusion Our negative findings in the Spanish population argue against the hypothesis that genetic variation in the tau protein phosphatase-2A (PP2A) pathway is causally related to AD risk

Published
2011
Full Text
View/download PDF

2. Detection of early Alzheimer's disease in MCI patients by the combination of MMSE and an episodic memory test

Author

Berciano José, González-Perez Soraya, Sánchez-Juan Pascual, Mateo Ignacio, Vazquez-Higuera José, Rodríguez-Rodríguez Eloy, Pozueta Ana, and Combarros Onofre

Subjects
Neurology. Diseases of the nervous system, RC346-429
Abstract

Abstract Background Mild cognitive impairment (MCI) is a heterogeneous clinical entity that comprises the prodromal phase of Alzheimer's disease (Pr-AD). New biomarkers are useful in detecting Pr-AD, but they are not universally available. We aimed to investigate baseline clinical and neuropsychological variables that might predict progression from MCI to AD dementia. Methods All patients underwent a complete clinical and neuropsychological evaluation at baseline and every 6 months during a two-year follow-up period, with 54 out of 109 MCI patients progressing to dementia (50 of them progressed to AD dementia), and 55 remaining as stable MCI (S-MCI). Results A combination of MMSE and California Verbal Learning Test Long Delayed Total Recall (CVLT-LDTR) constituted the best predictive model: subjects scoring above 26/30 on MMSE and 4/16 on CVLT-LDTR had a negative predictive value of 93.93% at 2 years, whereas those subjects scoring below both of these cut-off scores had a positive predictive value of 80.95%. Conclusions Pr-AD might be distinguished from S-MCI at baseline using the combination of MMSE and CVLT-LDTR. These two neuropsychological predictors are relatively brief and may be readily completed in non-specialist clinical settings.

Published
2011
Full Text
View/download PDF

3. Caspase-1 genetic variation is not associated with Alzheimer's disease risk

Author

Berciano José, Valdivieso Fernando, Frank Ana, Martínez-García Ana, Pozueta Ana, Mateo Ignacio, Sánchez-Juan Pascual, Rodríguez-Rodríguez Eloy, Vázquez-Higuera José, Bullido María J, and Combarros Onofre

Subjects
Internal medicine, RC31-1245, Genetics, QH426-470
Abstract

Abstract Background Interleukin (IL)-1β is a potent proinflammatory cytokine markedly overexpressed in the brains of patients with Alzheimer's disease (AD), and also involved in development of atherosclerosis and coronary artery disease. Caspase-1 (CASP1), formerly called IL-1β converting enzyme (ICE), mediates the cleavage of the inactive precursor of IL-1β into the biologically active form. CASP1 genetic variation (G+7/in6A, rs501192) has been associated with susceptibility to myocardial infarction and cardiovascular death risk. We examined the contribution of this gene to the susceptibility for AD. Methods We examined genetic variations of CASP1 by genotyping haplotype tagging SNPs (htSNPs) (rs501192, rs556205 and rs530537) in a group of 628 Spanish AD cases and 722 controls. Results There were no differences in the genotypic, allelic or haplotypic distributions between cases and controls in the overall analysis or after stratification by age, gender or APOE ε4 allele. Conclusion Our negative findings in the Spanish population argue against the hypothesis that CASP1 genetic variations are causally related to AD risk.

Published
2010
Full Text
View/download PDF

4. DYRK1A genetic variants are not linked to Alzheimer's disease in a Spanish case-control cohort

Author

Berciano José, Valdivieso Fernando, Sastre Isabel, Frank Ana, Pozueta Ana, Mateo Ignacio, Rodríguez-Rodríguez Eloy, Sánchez-Juan Pascual, Vázquez-Higuera José, Bullido María J, and Combarros Onofre

Subjects
Internal medicine, RC31-1245, Genetics, QH426-470
Abstract

Abstract Background As dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) has been implicated in the abnormal hyperphosphorylation of tau in Alzheimer's disease (AD) brain, and the development of neurofibrillary tangles, we examined the contribution of this gene to the susceptibility for AD. Methods We examined genetic variations of DYRK1A by genotyping haplotype tagging SNPs (htSNPs) (rs11701483, rs2835740, rs1137600, rs2835761, rs2835762, rs2154545 and rs8132976) in a group of 634 Spanish AD cases and 733 controls. Results There were no differences in the genotypic, allelic or haplotypic distributions between cases and controls in the overall analysis or after stratification by APOE ε4 allele. Conclusion Our negative findings in the Spanish population argue against the hypothesis that DYRK1A genetic variations are causally related to AD risk. Still, additional studies using different sets of patients and control subjects deserve further attention, since supporting evidence for association between DYRK1A gene and AD risk in the Japanese population exists.

Published
2009
Full Text
View/download PDF

5. The retinal ganglion cell layer reflects neurodegenerative changes in cognitively unimpaired individuals

Author

López-de-Eguileta, Alicia, López-García, Sara, Lage, Carmen, Pozueta, Ana, García-Martínez, María, Kazimierczak, Martha, Bravo, María, Irure, Juan, López-Hoyos, Marcos, Muñoz-Cacho, Pedro, Rodríguez-Perez, Noelia, Tordesillas-Gutiérrez, Diana, Goikoetxea, Alexander, Nebot, Claudia, Rodríguez-Rodríguez, Eloy, Casado, Alfonso, and Sánchez-Juan, Pascual

Published
2022
Full Text
View/download PDF

7. Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers

Author

Jansen, Iris, van der Lee, Sven J, Bellenguez, Céline, Ramakers, Inez, Rodriguez-Rodriguez, Eloy, Rujescu, Dan, Saltvedt, Ingvild, Sanchez-Juan, Pascual, Scheltens, Philip, Scherbaum, Norbert, Schmid, Matthias, Schneider, Anja, Selbæk, Geir, Kleineidam, Luca, Selnes, Per, Shadrin, Alexey, Skoog, Ingmar, Soininen, Hilkka, Tárraga, Lluís, Teipel, Stefan, group, GR@ACE study, Tijms, Betty, Tsolaki, Magda, Van Broeckhoven, Christine, Küçükali, Fahri, Van Dongen, Jasper, van Swieten, John C, Vandenberghe, Rik, Vidal, Jean-Sébastien, Visser, Pieter J, Vogelgsang, Jonathan, Waern, Margda, Wagner, Michael, Wiltfang, Jens, Wittens, Mandy M J, Sung, Yun Ju, Zetterberg, Henrik, Zulaica, Miren, van Duijn, Cornelia M, Bjerke, Maria, Engelborghs, Sebastiaan, Jessen, Frank, Teunissen, Charlotte E, Pastor, Pau, Hiltunen, Mikko, Ingelsson, Martin, Tesí, Niccolo, Andreassen, Ole A, Clarimón, Jordi, Sleegers, Kristel, Ruiz, Agustín, Ramirez, Alfredo, Cruchaga, Carlos, Lambert, Jean-Charles, van der Flier, Wiesje, Vromen, Ellen M, Wightman, Douglas P, Alcolea, Daniel, Alegret, Montserrat, Alvarez, Ignacio, Gomez-Fonseca, Duber, Amouyel, Philippe, Athanasiu, Lavinia, Bahrami, Shahram, Bailly, Henri, Belbin, Olivia, Bergh, Sverre, Bertram, Lars, Biessels, Geert Jan, Blennow, Kaj, Blesa, Rafael, de Rojas, Itziar, Boada, Mercè, Boland, Anne, Bürger, Katharina, Carracedo, Ángel, Cervera-Carles, Laura, Chene, Geneviève, Claassen, Jurgen A H R, Debette, Stephanie, Deleuze, Jean-Francois, de Deyn, Peter Paul, Dalmasso, Maria Carolina, Diehl-Schmid, Janine, Djurovic, Srdjan, Dols-Icardo, Oriol, Dufouil, Carole, Duron, Emmanuelle, Düzel, Emrah, consortium, EADB, Fladby, Tormod, Fortea, Juan, Frölich, Lutz, Grenier-Boley, Benjamin, García-González, Pablo, Garcia-Martinez, Maria, Giegling, Ina, Goldhardt, Oliver, Gobom, Johan, Grimmer, Timo, Haapasalo, Annakaisa, Hampel, Harald, Hanon, Olivier, Hausner, Lucrezia, Zettergren, Anna, Heilmann-Heimbach, Stefanie, Helisalmi, Seppo, Heneka, Michael, Hernández, Isabel, Herukka, Sanna-Kaisa, Holstege, Henne, Jarholm, Jonas, Kern, Silke, Knapskog, Anne-Brita, Koivisto, Anne M, Mishra, Aniket, Kornhuber, Johannes, Kuulasmaa, Teemu, Lage, Carmen, Laske, Christoph, Leinonen, Ville, Lewczuk, Piotr, Lleó, Alberto, de Munain, Adolfo López, Lopez-Garcia, Sara, Maier, Wolfgang, Ali, Muhammad, Marquié, Marta, Mol, Merel O, Montrreal, Laura, Moreno, Fermin, Moreno-Grau, Sonia, Nicolas, Gael, Nöthen, Markus M, Orellana, Adelina, Pålhaugen, Lene, Papma, Janne M, Andrade, Victor, Pasquier, Florence, Perneczky, Robert, Peters, Oliver, Pijnenburg, Yolande A L, Popp, Julius, Posthuma, Danielle, Pozueta, Ana, Priller, Josef, Puerta, Raquel, Quintela, Inés, Molecular Neuroscience and Ageing Research (MOLAR), Complex Trait Genetics, Amsterdam Neuroscience - Neurodegeneration, Amsterdam Neuroscience - Complex Trait Genetics, VU University medical center, Neurology, Human genetics, Amsterdam Neuroscience - Compulsivity, Impulsivity & Attention, Amsterdam Neuroscience - Brain Imaging, Laboratory Medicine, Amsterdam Neuroscience - Neuroinfection & -inflammation, APH - Personalized Medicine, APH - Methodology, RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, Psychology 2, Psychology 6, Pathologic Biochemistry and Physiology, Clinical Biology, Clinical sciences, Neuroprotection & Neuromodulation, European Commission, Clinical genetics, Amsterdam Reproduction & Development, Clinical chemistry, Department of Neurosciences, Clinicum, Helsinki University Hospital Area, University of Helsinki, HUS Neurocenter, Neurologian yksikkö, Epidemiology, and Universidad de Cantabria

Subjects
Neurologi, LD SCORE REGRESSION, Medizin, Cell Cycle Proteins, cerebrospinal fluid [Amyloid beta-Peptides], 3124 Neurology and psychiatry, pathology [Alzheimer Disease], Pathology, GWAS, RISK, NEURODEGENERATION, ASSOCIATION, Alzheimer's disease, AMYLOID-BETA, Cerebrospinal fluid, Neurology, cerebrospinal fluid [Biomarkers], Amyloid-beta, Life Sciences & Biomedicine, Alzheimer’s disease, EXPRESSION, Neuroscience(all), Clinical Neurology, tau Proteins, DIAGNOSIS, Pathology and Forensic Medicine, Cellular and Molecular Neuroscience, Apolipoproteins E, SDG 3 - Good Health and Well-being, Alzheimer Disease, Humans, ddc:610, cerebrospinal fluid [Peptide Fragments], Amyloid beta-Peptides, Science & Technology, MUTATIONS, neurology, 3112 Neurosciences, Neurosciences, GENE, Peptide Fragments, genetics [tau Proteins], cerebrospinal fluid [tau Proteins], TAU LEVELS, genetics [Apolipoproteins E], 3111 Biomedicine, Human medicine, Neurology (clinical), Neurosciences & Neurology, Tau, Biomarkers
Abstract

Amyloid-beta 42 (Aβ42) and phosphorylated tau (pTau) levels in cerebrospinal fluid (CSF) reflect core features of the pathogenesis of Alzheimer’s disease (AD) more directly than clinical diagnosis. Initiated by the European Alzheimer & Dementia Biobank (EADB), the largest collaborative effort on genetics underlying CSF biomarkers was established, including 31 cohorts with a total of 13,116 individuals (discovery n = 8074; replication n = 5042 individuals). Besides the APOE locus, novel associations with two other well-established AD risk loci were observed; CR1 was shown a locus for Aβ42 and BIN1 for pTau. GMNC and C16orf95 were further identified as loci for pTau, of which the latter is novel. Clustering methods exploring the influence of all known AD risk loci on the CSF protein levels, revealed 4 biological categories suggesting multiple Aβ42 and pTau related biological pathways involved in the etiology of AD. In functional follow-up analyses, GMNC and C16orf95 both associated with lateral ventricular volume, implying an overlap in genetic etiology for tau levels and brain ventricular volume. This work was supported by a grant (European Alzheimer DNA BioBank, EADB) from the EU Joint Programme, Neurodegenerative Disease Research (JPND). Amsterdam dementia Cohort (ADC): Research of the Alzheimer center Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. The Alzheimer Center Amsterdam is supported by Stichting Alzheimer Nederland and Stichting VUmc fonds. The clinical database structure was developed with funding from Stichting Dioraphte. Genotyping of the Dutch case-control samples was performed in the context of EADB (European Alzheimer DNA biobank) funded by the JPco-fuND FP-829-029 (ZonMW project number 733051061). Part of the work described in this study was carried out in the context of the Parelsnoer Institute (PSI). PSI was part of and funded by the Dutch Federation of University Medical Centers and has received initial funding from the Dutch Government (from 2007-2011). Since 2020, this work was carried out in the context of Parelsnoer clinical biobanks at Health-RI (https://www.health-ri.nl/initiatives/parelsnoer).Part of the genotyping included in this work was funded by the JPND EADB grant (German Federal Ministry of Education and Research (BMBF) grant: 01ED1619A). Alfredo Ramirez is also supported by the German Research Foundation (DFG) grants Nr: RA 1971/6-1, RA1971/7-1, and RA 1971/8-1. We would like to thank patients and controls who participated in this project. The Genome Research @ Fundacio ACE project (GR@ACE) is supported by Grifols SA, Fundacion bancaria 'La Caixa', Fundacio ACE, and CIBERNED. A.R. and M.B. receive support from the European Union/EFPIA Innovative Medicines Initiative Joint undertaking ADAPTED and MOPEAD projects (grant numbers 115975 and 115985, respectively). M.B. and A.R. are also supported by national grants PI13/02434, PI16/01861, PI17/01474, PI19/01240 and PI19/01301. Accion Estrategica en Salud is integrated into the Spanish National R + D + I Plan and funded by ISCIII (Instituto de Salud Carlos III)-Subdireccion General de Evaluacion and the Fondo Europeo de Desarrollo Regional (FEDER-'Una manera de hacer Europa'). The position held by I.dR. is funded by grant. FI20/00215. PFIS Contratos Predoctorales de Formacion en Investigacion en Salud. We would like to thank UCL Genomics, London, UK, for performing the genotyping analyses of the samples within the Gothenburg H70 Birth Cohort Studies and Clinical AD Sweden. The recruitment and clinical characterization of research participants at Washington University were supported by NIH P30AG066444, and P01AG003991. This work was supported by access to equipment made possible by the Hope Center for Neurological Disorders, the Neurogenomics and Informatics Center (NGI: https://neurogenom ics.wustl.edu/)and the Departments of Neurology and Psychiatry at Washington University School of Medicine. Research at the Belgian EADB site is funded in part by the Alzheimer Research Foundation (SAO-FRA), The Research Foundation Flanders (FWO), and the University of Antwerp Research Fund. FK is supported by a BOF DOCPRO fellowship of the University of Antwerp Research Fund. The work of Valdecilla was supported by grants from the Instituto de Salud Carlos III (Fondo de Investigacion Sanitario, PI08/0139, PI12/02288, PI16/01652, and PI20/01011), the JPND (DEMTEST PI11/03028), the CIBERNED, and the Siemens Healthineers. We thank the Valdecilla Biobank (PT17/0015/0019), integrated into the Spanish Biobank Network, for their support and collaboration in sample collection and management. Our heartfelt thanks to the participants of the Valdecilla Cohort for their generosity. The work of ADGEN was supported by EU Joint Programme-Neurodegenerative Disease Research (301220) and the Academy of Finland (338182). The DELCODE study (Study-ID:BN012) was supported and conducted by the German Center for Neurodegenerative Diseases (DZNE). The data samples were provided by the DELCODE study group. Details and participating sites can be found at www.dzne.de/en/research/studies/clinical-studies/delco de. The German Dementia Competence Network (KND) is funded by the German Federal Ministry of Education and Research (BMBF) grants Number: 01G10102, 01GI0420, 01GI0422, 01GI0423, 01GI0429, 01GI0431, 01GI0433, 04GI0434, 01GI0711. WF, SvdL, HHolstege, CT and PhS are recipients of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and HealthHolland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). More than 30 partners participate in ABOARD (www.aboard-project.nl).ABOARD also receives funding from de Hersenstichting, Edwin Bouw Fonds and Gieskes-Strijbisfonds. IEJ was partially supported by NWO Gravitation program BRAINSCAPES: A Roadmap from Neurogenetics to Neurobiology (NWO: 024.004.012). AZ was supported by the Swedish Alzheimer Foundation (AF-939988, AF-930582, AF-646061, AF-741361), and the Dementia Foundation (2020-04-13, 2021-0417). ISk was supported by the Swedish state under the agreement between the Swedish government and the county councils, the ALFagreement (ALF 716681), the Swedish Research Council (no 11267, 825-2012-5041, 2013-8717, 2015-02830, 2017-00639, 2019-01096), Swedish Research Council for Health, Working Life and Welfare (no 2001-2646, 2001-2835, 2001-2849, 2003-0234, 2004-0150, 20050762, 2006-0020, 2008-1229, 2008-1210, 2012-1138, 2004-0145, 2006-0596, 2008-1111, 2010-0870, 2013-1202, 2013-2300, 20132496), Swedish Brain Power, Hjarnfonden, Sweden (FO2016-0214, FO2018-0214, FO2019-0163), the Alzheimer's Association Zenith Award (ZEN-01-3151), the Alzheimer's Association Stephanie B. Overstreet Scholars (IIRG-00-2159), the Alzheimer's Association (IIRG-03-6168, IIRG-09-131338) and the Bank of Sweden Tercentenary Foundation. SK was supported by the Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (ALFGBG-81392, ALF GBG-771071), the Swedish Alzheimer Foundation (AF-842471, AF-737641, AF-939825), and the Swedish Research Council (2019-02075). MW was supported by the Swedish Research Council 2016-01590. DP was supported by BRAINSCAPES: A Roadmap from Neurogenetics to Neurobiology (grant no. 024.004.012), and a European Research Council advanced grant (Grant No, ERC-2018-AdG GWAS2FUNC 834057. HZ is a Wallenberg Scholar supported by grants from the Swedish Research Council (2018-02532), the European Research Council (681712), Swedish State Support for Clinical Research (ALFGBG-720931), the Alzheimer Drug Discovery Foundation (ADDF), USA (2018092016862), the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 860197 (MIRIADE), and the UK Dementia Research Institute at UCL. KB was supported by the Swedish Research Council (#2017-00915), the Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB201809-2016615), the Swedish Alzheimer Foundation (#AF-742881), Hjarnfonden, Sweden (#FO2017-0243), the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986), the European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236), the National Institute of Health (NIH), USA, (grant #1R01AG06839801), and the Alzheimer's Association 2021 Zenith Award (ZEN-21848495). CC receives support from the National Institutes of Health (R01AG044546, R01AG064877, RF1AG053303, R01AG058501, U01AG058922, RF1AG058501, R01AG064614), and the Chuck Zuckerberg Initiative (CZI).

Published
2022
Full Text
View/download PDF

9. Genome-wide meta-analysis for Alzheimer's disease cerebrospinal fluid biomarkers

Author

Jansen, Iris E., van der Lee, Sven J., Gomez-Fonseca, Duber, de Rojas, Itziar, Dalmasso, Maria Carolina, Grenier-Boley, Benjamin, Zettergren, Anna, Mishra, Aniket, Ali, Muhammad, Andrade, Victor, Bellenguez, Celine, Kleineidam, Luca, Kucukali, Fahri, Sung, Yun Ju, Tesi, Niccolo, Vromen, Ellen M., Wightman, Douglas P., Alcolea, Daniel, Alegret, Montserrat, Alvarez, Ignacio, Amouyel, Philippe, Athanasiu, Lavinia, Bahrami, Shahram, Bailly, Henri, Belbin, Olivia, Bergh, Sverre, Bertram, Lars, Biessels, Geert Jan, Blennow, Kaj, Blesa, Rafael, Boada, Merce, Boland, Anne, Buerger, Katharina, Carracedo, Angel, Cervera-Carles, Laura, Chene, Genevieve, Claassen, Jurgen A. H. R., Debette, Stephanie, Deleuze, Jean-Francois, de Deyn, Peter Paul, Diehl-Schmid, Janine, Djurovic, Srdjan, Dols-Icardo, Oriol, Dufouil, Carole, Duron, Emmanuelle, Duezel, Emrah, Fladby, Tormod, Fortea, Juan, Froelich, Lutz, Garcia-Gonzalez, Pablo, Garcia-Martinez, Maria, Giegling, Ina, Goldhardt, Oliver, Gobom, Johan, Grimmer, Timo, Haapasalo, Annakaisa, Hampel, Harald, Hanon, Olivier, Hausner, Lucrezia, Heilmann-Heimbach, Stefanie, Helisalmi, Seppo, Heneka, Michael T., Hernandez, Isabel, Herukka, Sanna-Kaisa, Holstege, Henne, Jarholm, Jonas, Kern, Silke, Knapskog, Anne-Brita, Koivisto, Anne M., Kornhuber, Johannes, Kuulasmaa, Teemu, Lage, Carmen, Laske, Christoph, Leinonen, Ville, Lewczuk, Piotr, Lleo, Alberto, de Munain, Adolfo Lopez, Lopez-Garcia, Sara, Maier, Wolfgang, Marquie, Marta, Mol, Merel O., Montrreal, Laura, Moreno, Fermin, Moreno-Grau, Sonia, Nicolas, Gael, Nothen, Markus M., Orellana, Adelina, Palhaugen, Lene, Papma, Janne M., Pasquier, Florence, Perneczky, Robert, Peters, Oliver, Pijnenburg, Yolande A. L., Popp, Julius, Posthuma, Danielle, Pozueta, Ana, Priller, Josef, Puerta, Raquel, Quintela, Ines, Ramakers, Inez, Rodriguez-Rodriguez, Eloy, Rujescu, Dan, Saltvedt, Ingvild, Sanchez-Juan, Pascual, Scheltens, Philip, Scherbaum, Norbert, Schmid, Matthias, Schneider, Anja, Selbaek, Geir, Selnes, Per, Shadrin, Alexey, Skoog, Ingmar, Soininen, Hilkka, Tarraga, Lluis, Teipel, Stefan, Tijms, Betty, Tsolaki, Magda, Van Broeckhoven, Christine, Van Dongen, Jasper, van Swieten, John C., Vandenberghe, Rik, Vidal, Jean-Sebastien, Visser, Pieter J., Vogelgsang, Jonathan, Waern, Margda, Wagner, Michael, Wiltfang, Jens, Wittens, Mandy M. J., Zetterberg, Henrik, Zulaica, Miren, van Duijn, Cornelia M., Bjerke, Maria, Engelborghs, Sebastiaan, Jessen, Frank, Teunissen, Charlotte E., Pastor, Pau, Hiltunen, Mikko, Ingelsson, Martin, Andreassen, Ole A., Clarimon, Jordi, Sleegers, Kristel, Ruiz, Agustin, Ramirez, Alfredo, Cruchaga, Carlos, Lambert, Jean-Charles, van der Flier, Wiesje, Jansen, Iris E., van der Lee, Sven J., Gomez-Fonseca, Duber, de Rojas, Itziar, Dalmasso, Maria Carolina, Grenier-Boley, Benjamin, Zettergren, Anna, Mishra, Aniket, Ali, Muhammad, Andrade, Victor, Bellenguez, Celine, Kleineidam, Luca, Kucukali, Fahri, Sung, Yun Ju, Tesi, Niccolo, Vromen, Ellen M., Wightman, Douglas P., Alcolea, Daniel, Alegret, Montserrat, Alvarez, Ignacio, Amouyel, Philippe, Athanasiu, Lavinia, Bahrami, Shahram, Bailly, Henri, Belbin, Olivia, Bergh, Sverre, Bertram, Lars, Biessels, Geert Jan, Blennow, Kaj, Blesa, Rafael, Boada, Merce, Boland, Anne, Buerger, Katharina, Carracedo, Angel, Cervera-Carles, Laura, Chene, Genevieve, Claassen, Jurgen A. H. R., Debette, Stephanie, Deleuze, Jean-Francois, de Deyn, Peter Paul, Diehl-Schmid, Janine, Djurovic, Srdjan, Dols-Icardo, Oriol, Dufouil, Carole, Duron, Emmanuelle, Duezel, Emrah, Fladby, Tormod, Fortea, Juan, Froelich, Lutz, Garcia-Gonzalez, Pablo, Garcia-Martinez, Maria, Giegling, Ina, Goldhardt, Oliver, Gobom, Johan, Grimmer, Timo, Haapasalo, Annakaisa, Hampel, Harald, Hanon, Olivier, Hausner, Lucrezia, Heilmann-Heimbach, Stefanie, Helisalmi, Seppo, Heneka, Michael T., Hernandez, Isabel, Herukka, Sanna-Kaisa, Holstege, Henne, Jarholm, Jonas, Kern, Silke, Knapskog, Anne-Brita, Koivisto, Anne M., Kornhuber, Johannes, Kuulasmaa, Teemu, Lage, Carmen, Laske, Christoph, Leinonen, Ville, Lewczuk, Piotr, Lleo, Alberto, de Munain, Adolfo Lopez, Lopez-Garcia, Sara, Maier, Wolfgang, Marquie, Marta, Mol, Merel O., Montrreal, Laura, Moreno, Fermin, Moreno-Grau, Sonia, Nicolas, Gael, Nothen, Markus M., Orellana, Adelina, Palhaugen, Lene, Papma, Janne M., Pasquier, Florence, Perneczky, Robert, Peters, Oliver, Pijnenburg, Yolande A. L., Popp, Julius, Posthuma, Danielle, Pozueta, Ana, Priller, Josef, Puerta, Raquel, Quintela, Ines, Ramakers, Inez, Rodriguez-Rodriguez, Eloy, Rujescu, Dan, Saltvedt, Ingvild, Sanchez-Juan, Pascual, Scheltens, Philip, Scherbaum, Norbert, Schmid, Matthias, Schneider, Anja, Selbaek, Geir, Selnes, Per, Shadrin, Alexey, Skoog, Ingmar, Soininen, Hilkka, Tarraga, Lluis, Teipel, Stefan, Tijms, Betty, Tsolaki, Magda, Van Broeckhoven, Christine, Van Dongen, Jasper, van Swieten, John C., Vandenberghe, Rik, Vidal, Jean-Sebastien, Visser, Pieter J., Vogelgsang, Jonathan, Waern, Margda, Wagner, Michael, Wiltfang, Jens, Wittens, Mandy M. J., Zetterberg, Henrik, Zulaica, Miren, van Duijn, Cornelia M., Bjerke, Maria, Engelborghs, Sebastiaan, Jessen, Frank, Teunissen, Charlotte E., Pastor, Pau, Hiltunen, Mikko, Ingelsson, Martin, Andreassen, Ole A., Clarimon, Jordi, Sleegers, Kristel, Ruiz, Agustin, Ramirez, Alfredo, Cruchaga, Carlos, Lambert, Jean-Charles, and van der Flier, Wiesje

Abstract

Amyloid-beta 42 (A beta 42) and phosphorylated tau (pTau) levels in cerebrospinal fluid (CSF) reflect core features of the pathogenesis of Alzheimer's disease (AD) more directly than clinical diagnosis. Initiated by the European Alzheimer & Dementia Biobank (EADB), the largest collaborative effort on genetics underlying CSF biomarkers was established, including 31 cohorts with a total of 13,116 individuals (discovery n = 8074; replication n = 5042 individuals). Besides the APOE locus, novel associations with two other well-established AD risk loci were observed; CR1 was shown a locus for A beta 42 and BIN1 for pTau. GMNC and C16orf95 were further identified as loci for pTau, of which the latter is novel. Clustering methods exploring the influence of all known AD risk loci on the CSF protein levels, revealed 4 biological categories suggesting multiple A beta 42 and pTau related biological pathways involved in the etiology of AD. In functional follow-up analyses, GMNC and C16orf95 both associated with lateral ventricular volume, implying an overlap in genetic etiology for tau levels and brain ventricular volume.

Published
2022

10. Genome-wide meta-analysis for Alzheimer's disease cerebrospinal fluid biomarkers

Author

Jansen, Ris E., van der Lee, Sven J., Gomez-Fonseca, Duber, de Rojas, Itziar, Dalmasso, Maria Carolina, Grenier-Boley, Benjamin, Zettergren, Anna, Mishra, Aniket, Ali, Muhammad, Andrade, Victor, Bellenguez, Celine, Kleineidam, Luca, Kucukali, Fahri, Sung, Yun Ju, Tesi, Niccolo, Vromen, Ellen M., Wightman, Douglas P., Alcolea, Daniel, Alegret, Montserrat, Alvarez, Ignacio, Amouyel, Philippe, Athanasiu, Lavinia, Bahrami, Shahram, Bailly, Henri, Belbin, Olivia, Bergh, Sverre, Bertram, Lars, Biessels, Geert Jan, Blennow, Kaj, Blesa, Rafael, Boada, Merce, Boland, Anne, Buerger, Katharina, Carracedo, Angel, Cervera-Carles, Laura, Chene, Genevieve, Claassen, Jurgen A. H. R., Debette, Stephanie, Deleuze, Jean-Francois, de Deyn, Peter Paul, Diehl-Schmid, Janine, Djurovic, Srdjan, Dols-Icardo, Oriol, Dufouil, Carole, Duron, Emmanuelle, Duezel, Emrah, Fladby, Tormod, Fortea, Juan, Froelich, Lutz, Garcia-Gonzalez, Pablo, Garcia-Martinez, Maria, Giegling, Ina, Goldhardt, Oliver, Gobom, Johan, Grimmer, Timo, Haapasalo, Annakaisa, Hampel, Harald, Hanon, Olivier, Hausner, Lucrezia, Heilmann-Heimbach, Stefanie, Helisalmi, Seppo, Heneka, Michael T., Hernandez, Isabel, Herukka, Sanna-Kaisa, Holstege, Henne, Jarholm, Jonas, Kern, Silke, Knapskog, Anne-Brita, Koivisto, Anne M., Kornhuber, Johannes, Kuulasmaa, Teemu, Lage, Carmen, Laske, Christoph, Leinonen, Ville, Lewczuk, Piotr, Lleo, Alberto, de Munain, Adolfo Lopez, Lopez-Garcia, Sara, Maier, Wolfgang, Marquie, Marta, Mol, Merel O., Montrreal, Laura, Moreno, Fermin, Moreno-Grau, Sonia, Nicolas, Gael, Nothen, Markus M., Orellana, Adelina, Palhaugen, Lene, Papma, Janne M., Pasquier, Florence, Perneczky, Robert, Peters, Oliver, Pijnenburg, Yolande A. L., Popp, Julius, Posthuma, Danielle, Pozueta, Ana, Priller, Josef, Puerta, Raquel, Quintela, Ines, Ramakers, Inez, Rodriguez-Rodriguez, Eloy, Rujescu, Dan, Saltvedt, Ingvild, Sanchez-Juan, Pascual, Scheltens, Philip, Scherbaum, Norbert, Schmid, Matthias, Schneider, Anja, Selbaek, Geir, Selnes, Per, Shadrin, Alexey, Skoog, Ingmar, Soininen, Hilkka, Tarraga, Lluis, Teipel, Stefan, Tijms, Betty, Tsolaki, Magda, Van Broeckhoven, Christine, Van Dongen, Jasper, van Swieten, John C., Vandenberghe, Rik, Vidal, Jean-Sebastien, Visser, Pieter J., Vogelgsang, Jonathan, Waern, Margda, Wagner, Michael, Wiltfang, Jens, Wittens, Mandy M. J., Zetterberg, Henrik, Zulaica, Miren, van Duijn, Cornelia M., Bjerke, Maria, Engelborghs, Sebastiaan, Jessen, Frank, Teunissen, Charlotte E., Pastor, Pau, Hiltunen, Mikko, Ingelsson, Martin, Andreassen, Ole A., Clarimon, Jordi, Sleegers, Kristel, Ruiz, Agustin, Ramirez, Alfredo, Cruchaga, Carlos, Lambert, Jean-Charles, van der Flier, Wiesje, Jansen, Ris E., van der Lee, Sven J., Gomez-Fonseca, Duber, de Rojas, Itziar, Dalmasso, Maria Carolina, Grenier-Boley, Benjamin, Zettergren, Anna, Mishra, Aniket, Ali, Muhammad, Andrade, Victor, Bellenguez, Celine, Kleineidam, Luca, Kucukali, Fahri, Sung, Yun Ju, Tesi, Niccolo, Vromen, Ellen M., Wightman, Douglas P., Alcolea, Daniel, Alegret, Montserrat, Alvarez, Ignacio, Amouyel, Philippe, Athanasiu, Lavinia, Bahrami, Shahram, Bailly, Henri, Belbin, Olivia, Bergh, Sverre, Bertram, Lars, Biessels, Geert Jan, Blennow, Kaj, Blesa, Rafael, Boada, Merce, Boland, Anne, Buerger, Katharina, Carracedo, Angel, Cervera-Carles, Laura, Chene, Genevieve, Claassen, Jurgen A. H. R., Debette, Stephanie, Deleuze, Jean-Francois, de Deyn, Peter Paul, Diehl-Schmid, Janine, Djurovic, Srdjan, Dols-Icardo, Oriol, Dufouil, Carole, Duron, Emmanuelle, Duezel, Emrah, Fladby, Tormod, Fortea, Juan, Froelich, Lutz, Garcia-Gonzalez, Pablo, Garcia-Martinez, Maria, Giegling, Ina, Goldhardt, Oliver, Gobom, Johan, Grimmer, Timo, Haapasalo, Annakaisa, Hampel, Harald, Hanon, Olivier, Hausner, Lucrezia, Heilmann-Heimbach, Stefanie, Helisalmi, Seppo, Heneka, Michael T., Hernandez, Isabel, Herukka, Sanna-Kaisa, Holstege, Henne, Jarholm, Jonas, Kern, Silke, Knapskog, Anne-Brita, Koivisto, Anne M., Kornhuber, Johannes, Kuulasmaa, Teemu, Lage, Carmen, Laske, Christoph, Leinonen, Ville, Lewczuk, Piotr, Lleo, Alberto, de Munain, Adolfo Lopez, Lopez-Garcia, Sara, Maier, Wolfgang, Marquie, Marta, Mol, Merel O., Montrreal, Laura, Moreno, Fermin, Moreno-Grau, Sonia, Nicolas, Gael, Nothen, Markus M., Orellana, Adelina, Palhaugen, Lene, Papma, Janne M., Pasquier, Florence, Perneczky, Robert, Peters, Oliver, Pijnenburg, Yolande A. L., Popp, Julius, Posthuma, Danielle, Pozueta, Ana, Priller, Josef, Puerta, Raquel, Quintela, Ines, Ramakers, Inez, Rodriguez-Rodriguez, Eloy, Rujescu, Dan, Saltvedt, Ingvild, Sanchez-Juan, Pascual, Scheltens, Philip, Scherbaum, Norbert, Schmid, Matthias, Schneider, Anja, Selbaek, Geir, Selnes, Per, Shadrin, Alexey, Skoog, Ingmar, Soininen, Hilkka, Tarraga, Lluis, Teipel, Stefan, Tijms, Betty, Tsolaki, Magda, Van Broeckhoven, Christine, Van Dongen, Jasper, van Swieten, John C., Vandenberghe, Rik, Vidal, Jean-Sebastien, Visser, Pieter J., Vogelgsang, Jonathan, Waern, Margda, Wagner, Michael, Wiltfang, Jens, Wittens, Mandy M. J., Zetterberg, Henrik, Zulaica, Miren, van Duijn, Cornelia M., Bjerke, Maria, Engelborghs, Sebastiaan, Jessen, Frank, Teunissen, Charlotte E., Pastor, Pau, Hiltunen, Mikko, Ingelsson, Martin, Andreassen, Ole A., Clarimon, Jordi, Sleegers, Kristel, Ruiz, Agustin, Ramirez, Alfredo, Cruchaga, Carlos, Lambert, Jean-Charles, and van der Flier, Wiesje

Abstract

Amyloid-beta 42 (A beta 42) and phosphorylated tau (pTau) levels in cerebrospinal fluid (CSF) reflect core features of the pathogenesis of Alzheimer's disease (AD) more directly than clinical diagnosis. Initiated by the European Alzheimer & Dementia Biobank (EADB), the largest collaborative effort on genetics underlying CSF biomarkers was established, including 31 cohorts with a total of 13,116 individuals (discovery n = 8074; replication n = 5042 individuals). Besides the APOE locus, novel associations with two other well-established AD risk loci were observed; CR1 was shown a locus for A beta 42 and BIN1 for pTau. GMNC and C16orf95 were further identified as loci for pTau, of which the latter is novel. Clustering methods exploring the influence of all known AD risk loci on the CSF protein levels, revealed 4 biological categories suggesting multiple A beta 42 and pTau related biological pathways involved in the etiology of AD. In functional follow-up analyses, GMNC and C16orf95 both associated with lateral ventricular volume, implying an overlap in genetic etiology for tau levels and brain ventricular volume.

Published
2022

12. Additional file 1 of The retinal ganglion cell layer reflects neurodegenerative changes in cognitively unimpaired individuals

Author

López-de-Eguileta, Alicia, López-García, Sara, Lage, Carmen, Pozueta, Ana, García-Martínez, María, Kazimierczak, Martha, Bravo, María, Irure, Juan, López-Hoyos, Marcos, Muñoz-Cacho, Pedro, Rodríguez-Perez, Noelia, Tordesillas-Gutiérrez, Diana, Goikoetxea, Alexander, Nebot, Claudia, Rodríguez-Rodríguez, Eloy, Casado, Alfonso, and Sánchez-Juan, Pascual

Abstract

Additional file 1. Ophthalmological variables analysis as possible confounders. Potential confounders were evaluated by comparing ophthalmological variables (like IOP, pachymetry, AL and refractive error) in individuals with positive versus negative AD biomarkers. These variables did not show significant associations with CSF AD biomarkers.

Published
2022
Full Text
View/download PDF

13. Sleep Time Estimated by an Actigraphy Watch Correlates With CSF Tau in Cognitively Unimpaired Elders: The Modulatory Role of APOE

Author

López-García, Sara, primary, Lage, Carmen, additional, Pozueta, Ana, additional, García-Martínez, María, additional, Kazimierczak, Martha, additional, Fernández-Rodríguez, Andrea, additional, Bravo, María, additional, Reyes-González, Luis, additional, Irure, Juan, additional, López-Hoyos, Marcos, additional, Rodríguez-Rodríguez, Eloy, additional, and Sánchez-Juan, Pascual, additional

Published
2021
Full Text
View/download PDF

14. Distinctive Oculomotor Behaviors in Alzheimer's Disease and Frontotemporal Dementia

Author

Lage, Carmen, López-García, Sara, Bejanin, Alexandre, Kazimierczak, Martha, Aracil-Bolaños, Ignacio, Calvo-Córdoba, Alberto, Pozueta, Ana, García-Martínez, María, Fernández-Rodríguez, Andrea, Bravo-González, María, Jiménez-Bonilla, Julio, Banzo, Ignacio, Irure-Ventura, Juan, Pegueroles, Jordi, Illán-Gala, Ignacio, Fortea, Juan, Rodríguez-Rodríguez, Eloy, Lleó, Alberto, García-Cena, Cecilia E., Sánchez-Juan, Pascual, Universitat Autònoma de Barcelona, Lage, Carmen, López-García, Sara, Bejanin, Alexandre, Kazimierczak, Martha, Aracil-Bolaños, Ignacio, Calvo-Córdoba, Alberto, Pozueta, Ana, García-Martínez, María, Fernández-Rodríguez, Andrea, Bravo-González, María, Jiménez-Bonilla, Julio, Banzo, Ignacio, Irure-Ventura, Juan, Pegueroles, Jordi, Illán-Gala, Ignacio, Fortea, Juan, Rodríguez-Rodríguez, Eloy, Lleó, Alberto, García-Cena, Cecilia E., Sánchez-Juan, Pascual, and Universitat Autònoma de Barcelona

Abstract

Oculomotor behavior can provide insight into the integrity of widespread cortical networks, which may contribute to the differential diagnosis between Alzheimer's disease and frontotemporal dementia. Three groups of patients with Alzheimer's disease, behavioral variant of frontotemporal dementia (bvFTD) and semantic variant of primary progressive aphasia (svPPA) and a sample of cognitively unimpaired elders underwent an eye-tracking evaluation. All participants in the discovery sample, including controls, had a biomarker-supported diagnosis. Oculomotor correlates of neuropsychology and brain metabolism evaluated with 18F-FDG PET were explored. Machine-learning classification algorithms were trained for the differentiation between Alzheimer's disease, bvFTD and controls. A total of 93 subjects (33 Alzheimer's disease, 24 bvFTD, seven svPPA, and 29 controls) were included in the study. Alzheimer's disease was the most impaired group in all tests and displayed specific abnormalities in some visually-guided saccade parameters, as pursuit error and horizontal prosaccade latency, which are theoretically closely linked to posterior brain regions. BvFTD patients showed deficits especially in the most cognitively demanding tasks, the antisaccade and memory saccade tests, which require a fine control from frontal lobe regions. SvPPA patients performed similarly to controls in most parameters except for a lower number of correct memory saccades. Pursuit error was significantly correlated with cognitive measures of constructional praxis and executive function and metabolism in right posterior middle temporal gyrus. The classification algorithms yielded an area under the curve of 97.5% for the differentiation of Alzheimer's disease vs. controls, 96.7% for bvFTD vs. controls, and 92.5% for Alzheimer's disease vs. bvFTD. In conclusion, patients with Alzheimer's disease, bvFTD and svPPA exhibit differentiating oculomotor patterns which reflect the characteristic neuroanatomical dis

Published
2021

15. Distinctive Oculomotor Behaviors in Alzheimer's Disease and Frontotemporal Dementia

Author

Lage, Carmen, primary, López-García, Sara, additional, Bejanin, Alexandre, additional, Kazimierczak, Martha, additional, Aracil-Bolaños, Ignacio, additional, Calvo-Córdoba, Alberto, additional, Pozueta, Ana, additional, García-Martínez, María, additional, Fernández-Rodríguez, Andrea, additional, Bravo-González, María, additional, Jiménez-Bonilla, Julio, additional, Banzo, Ignacio, additional, Irure-Ventura, Juan, additional, Pegueroles, Jordi, additional, Illán-Gala, Ignacio, additional, Fortea, Juan, additional, Rodríguez-Rodríguez, Eloy, additional, Lleó-Bisa, Alberto, additional, García-Cena, Cecilia E., additional, and Sánchez-Juan, Pascual, additional

Published
2021
Full Text
View/download PDF

16. Safety and preliminary efficacy on cognitive performance and adaptive functionality of epigallocatechin gallate (EGCG) in children with Down syndrome. A randomized phase Ib clinical trial (PERSEUS study)

Author

Cieuta-Walti, Cécile, Cuenca-Royo, Aida, Langohr, Klaus, Rakic, Claire, López-Vílchez, MaÁngeles, Lirio, Julián, González-Lamuño Leguina, Domingo, González, Teresa Bermejo, García, Jordi García, Roure, Maria Rimblas, Aldea-Perona, Ana, Forcano, Laura, Gomis-Gonzalez, Maria, Cés, Sebastià Videla, Lacaille, Florence, Ravel, Aimé, Mircher, Clotilde, Walti, Hervé, Janel, Nathalie, Dairou, Julien, Lévy, Marilyne, Durand, Sophie, Dierssen, Mara, Sacco, Silvia, Fornell, Rafael de la Torre, Guerrico, Ion Álvarez, Goday, Albert, Llop, Cristina, Mateus, Julián, Matilla, Iris, Esther, Menoyo, Hernández-Ligero, Lorena, Pérez, Marta, Pizarro, Neus, Principe, Alessandro, Cortesi, Anna, Gomez, Alba, Paredes, Noelia, Gomez, Cristina, Graell, Montserrat, López, Pilar, Lozano, Rosario, Medrano, Constancio, Andrade-Navarro, Maria Teresa, Daza, Gema, Garcia, Sandra, Gayán, Ma Luisa, Guerra-Colorado, Cristina, Luna, Beatriz, Maya, Enriqueta, Millan, Delia, Reina, Macarena, Amigo, María Teresa, Fernández, José Luís, García-Martínez, María, Pérez-Poyato, María del Socorro, Pozueta, Ana, Tato, Emma, Viadero, María Teresa, Akkaya, Magnolia, Falquero, Ségolène, Gambarini, Alicia, Akkaya, Magnolia, Falquero, Ségolène, and Gambarini, Alicia

Abstract

Although some caregivers are using epigallocatechin gallate (EGCG) off label in hopes of improving cognition in young adults with Down syndrome (DS), nothing is known about its safety, tolerability, and efficacy in the DS pediatric population. We aimed to evaluate safety and tolerability of a dietary supplement containing EGCG and if EGCG improves cognitive and functional performance.

Published
2022
Full Text
View/download PDF

17. Evaluation of choroidal thickness in prodromal Alzheimer’s disease defined by amyloid PET

Author

López-de-Eguileta, Alicia, primary, Lage, Carmen, additional, López-García, Sara, additional, Pozueta, Ana, additional, García-Martínez, María, additional, Kazimierczak, Martha, additional, Bravo, María, additional, de Arcocha-Torres, María, additional, Banzo, Ignacio, additional, Jimenez-Bonilla, Julio, additional, Cerveró, Andrea, additional, Goikoetxea, Alexander, additional, Rodríguez-Rodríguez, Eloy, additional, Sánchez-Juan, Pascual, additional, and Casado, Alfonso, additional

Published
2020
Full Text
View/download PDF

20. Heterogeneous Catalytic and Photocatalytic Nitrate Abatement in Drinking Water Using Agpt and Pdsn Supported on Titania Nanocatalysts. Éliminitation du Nitrate dans l'eau Potable par Catalyse Hétèrogène et Photocatalyse au Moyen de Nanocatalyseurs AgPt et

Author

Antolín Pozueta, Ana María, Departament d'Enginyeria Química, Universitat Rovira i Virgili., Contreras Iglesias, Sandra, Medina Cabello, Francisco, Tichit, Didier, and Universitat Rovira i Virgili. Departament d'Enginyeria Química

Subjects
Catàlisi/Fotocatàlisi, Ciències, Drinking water, Denitration, Catalysis/Photocatalysis, Aigüa potable, Desnitració, Desnitración
Abstract

La desnitració d’aigües a gas N2 i H2O usant processos catalítics i foto-catalítics, ha estat investigat en presencia/absència de hidrogen com a gas reductor. Els catalitzadors utilitzats van ser: catalitzadors mono-metàl•lics (Ag/P25, Pt/P25); una barreja física dels catalitzadors mono-metàl•lics (Ag/P25 + Pt/P25); i catalitzadors bimetàl•lics (Ag-Pt(Pt-Ag)/P25 i Pd-Sn/P25). Aquests catalitzadors van ser suportats en Titania P25 amb l’objectiu de demostrar la seva versatilitat en els dos processos (catalític y foto-catalític) per a complir la normativa de la Unió Europea (UE) per a compostos de nitrogen en aigua potable (50 mg/L NO3-, 0.5 mg/L NO2-, 0.3 mg/L NH4+). L’efecte de la quantitat de metall (Ag,Pt), el precursor de Pt (H2PtCl6∙6H2O; K2PtCl6), l’ordre d’impregnació (Ag-Pt,Pt-Ag), i la morfologia (Pd-Sn nano-partícules esfèriques (NPs) i nano-bastons (NRs)) van ser examinades mitjançant diverses tècniques de caracterització (DRX, Fisisorció de N2, MET, DRUV-Vis, XPS, H2-TPR y Quimisorció de H2). Es va aconseguir una bona selectivitat per a N2 (76%) en el procés catalític, utilitzant la mescla de Ag(2)/P25 + Pt(4)/P25(H), però tot i això, es va obtenir també un 13% de NO2-. Els catalitzadors bimetàl•lics van mostrar versatilitat, sent actius en els dos processos. La selectivitat a N2 va ser major amb els NRs (51%) que amb les NPs esfèriques (32%). El Pt(4)-Ag(2)/P25(K) presenta la major selectivitat al N2 (80%). Més estudis són necessaris per a poder reduir els rendiments de NO2- i NH4+., La desnitración de las aguas para la obtención de N2 y H2O ha sido investigada mediante procesos catalíticos y fotocatalíticos, en presencia y ausencia de hidrógeno, el cual se ha usado como agente reductor. Los catalizadores que se utilizaron son: catalizadores monometálicos (Ag/P25, Pt/P25); una mezcla física de los catalizadores monometálicos anteriores (Ag/P25 + Pt/P25); y catalizadores bimetálicos (Ag-Pt (Pt-Ag)/P25 and Pd-Sn/P25). Los catalizadores se soportaron sobre la Titania P25 con el objetivo de probar su posible efectividad en los dos procesos (catalítico y fotocatalítico), para cumplir con la normativa de la Union Europea (UE) sobre compuestos nitrogenados en aguas potables (50 mg/L NO3-, 0.5 mg/L NO2-, 0.3 mg/L NH4+). El efecto de la carga metálica (Ag, Pt), el precursor de Pt (H2PtCl6∙6H2O o K2PtCl6), el orden de impregnación (Ag-Pt, Pt-Ag), y la morfología (Pd-Sn NPs esféricas and nanobastones (NRs)) han sido examinados utilizando varias técnicas de caracterización (DRX, Fisisorción de N2, MET, DRUV-Vis, XPS, H2-TPR y Quimisorción de H2). Se obtuvo una buena selectividad a N2 (76%) en condiciones catalíticas con la mezcla física Ag(2)/P25+Pt(4)/P25(H), pero con un rendimiento a NO2- del ca. 13%. Los catalizadores bimetálicos se mostraron activos en los dos procesos. La selectividad a N2 fue mayor con los NRs (51%) que con las NPs esféricas (32%). El catalizador Pt(4)-Ag(2)/P25(K) presenta la selectividad más alta a N2 (80%). Más estudios necesitan realizarse para disminuir las concentraciones de NO2- and NH4+., Denitration of water towards N2 gas and H2O has been investigated by catalytic and photocatalytic processes in presence/absence of hydrogen as reducing agent. The catalysts used were: monometallic catalysts (Ag/P25, Pt/P25); physical mixture of both monometallics (Ag/P25 + Pt/P25); and bimetallic catalysts (Ag-Pt(Pt-Ag)/P25 and Pd-Sn/P25). These catalysts were supported on Titania P25 with the aim of testing their versatility in both catalytic and photocatalytic processes to accomplish the EU Normative for N-compounds in drinking water (50 mg/L NO3-, 0.5 mg/L NO2-, 0.3 mg/L NH4+). The effect of the metal loading (Ag,Pt), Pt precursor (H2PtCl6∙6H2O; K2PtCl6), impregnation order (Ag-Pt,Pt-Ag), and morphology (Pd-Sn spherical NPs and nanorods (NRs)) were examined through various characterization techniques(XRD, N2- physisorption, TEM, DRUV-Vis, XPS, H2-TPR y H2- Chimisorption). Good N2 selectivity (76%) in the catalytic process was achieved with the Ag(2)/P25+Pt(4)/P25(H) mixture but with ca. 13% NO2- yield. Bimetallic catalysts show versatility being active in both processes. The selectivity to nitrogen for NRs was higher (51%) than that for spherical NPs (32%). Pt(4)-Ag(2)/P25(K) presented the highest selectivity to N2 (80%). Further studies are still needed to decrease NO2- and NH4+ yields.

Published
2016

21. MAPT H1 haplotype is associated with late-onset Alzheimer's disease risk in APOE ε 4 noncarriers: Results from the dementia genetics Spanish consortium

Author

Pastor, Pau, Moreno, Fermín, Antonell, Anna, Elcoroaristizabal, Xabier, Lleó, Alberto, Blesa, Rafael, Fortea, Juan, Belbin, Olivia, Alcolea, Daniel, Carmona-Iragui, María, Sánchez-Saudinós, M Belén, Sala, Isabel, Anton-Aguirre, Sofía, Coto, Eliecer, Morenas, Estrella, Ribosa, Roser, Colom-Cadena, Martí, Cervera, Laura, Muñoz, Laia, Dols-Icardo, Oriol, Clarimón, Jordi, Ortega-Cubero, Sara, Hernandez, Isabel, Tárraga, Lluís, Boada, Mercè, Kulisevsky, Jaime, Vázquez-Higuera, José Luis, Infante, Jon, Rábano, Alberto, Fernández-Blázquez, Miguel Ángel, Valentí, Meritxell, Indakoetxea, Begoña, Barandiarán, Myriam, Gorostidi, Ana, Frank-García, Ana, Sastre, Isabel, Lorenzo, Elena, Ruiz, Agustín, Pastor, María A, Lennarz, Martina, Maier, Wolfgang, Rámirez, Alfredo, Serrano-Ríos, Manuel, Lee, Suzee E, Sánchez-Juan, Pascual, Consortium, Dementia Genetic Spanish, Combarros, Onofre, Lorenzo-Betancor, Oswaldo, Pastor, Maria A, Hernández, Isabel, Lafuente, Asunción, Rosende-Roca, Maitée, Mauleón, Ana, Vargas, Liliana, Rodríguez, Octavio, Calero, Miguel, Abdelnour, Carla, Alegret, Montserrat, Espinosa, Ana, Ortega, Gemma, Sanabria, Ángela, Ibarria, Marta, Diego, Susana, Canyabate, Pilar, Moreno, Mariola, Buendía, Mar, López de Munain, Adolfo, Pancho, Ana, Palacio, María Eugenia, Ruiz, Susana, Tantinya, Natalia, Tarragona, Marina, Morera, América, Guitart, Marina, Sotolongo Grau, Oscar, Martín, Elvira, Fernández, Victòria, Bullido, Maria J, Sánchez-Valle, Raquel, Molinuevo, José Luis, Lladó, Albert, Rami, Lorena, Alvarez, Victoria, de Pancorbo, Marian M, Pozueta, Ana, González Suarez, Andrea, Carro, Eva, Rodriguez-Rodriguez, Eloy, Mateo, Ignacio, Berciano, José, Bullido, María J, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación (España), Universidad Pública de Navarra, Universidad del País Vasco, Universidad Autónoma de Madrid, Fundació ACE. Institut Català de Neurociències Aplicades, University of Bonn, University of California, Universitat de Barcelona, Universitat Autònoma de Barcelona, and Universitat Oberta de Catalunya (UOC)

Subjects
Gerontology, Male, associació genètica, genetic association, Apolipoprotein E4, A152T, enfermedad de Alzheimer, genetics [Alzheimer Disease], frontotemporal dementia, MAPT, Alzheimer, Enfermedad de, genetics [Genetic Predisposition to Disease], genetics [Frontotemporal Dementia], genetics [Apolipoprotein E4], Aged, 80 and over, General Neuroscience, General Medicine, demencia frontotemporal, Middle Aged, Alzheimer's disease, Psychiatry and Mental health, Clinical Psychology, demència frontotemporal, genetics [Polymorphism, Single Nucleotide], Christian ministry, Female, Alzheimer’s disease, Frontotemporal dementia, Late onset, MAPT protein, human, tau Proteins, Polymorphism, Single Nucleotide, asociación genética, Alzheimer Disease, malaltia d'Alzheimer, mental disorders, medicine, Dementia, Humans, Genetic Predisposition to Disease, ddc:610, Genetic association, Aged, business.industry, Haplotype, medicine.disease, nervous system diseases, H1H2, genetics [tau Proteins], Alzheimer, Malaltia d', Logistic Models, Haplotypes, Spain, Disease risk, Geriatrics and Gerontology, business
Abstract

The MAPT H1 haplotype has been linked to several disorders, but its relationship with Alzheimer's disease (AD) remains controversial. A rare variant in MAPT (p.A152T) has been linked with frontotemporal dementia (FTD) and AD. We genotyped H1/H2 and p.A152T MAPT in 11,572 subjects from Spain (4,327 AD, 563 FTD, 648 Parkinson's disease (PD), 84 progressive supranuclear palsy (PSP), and 5,950 healthy controls). Additionally, we included 101 individuals from 21 families with genetic FTD. MAPT p.A152T was borderline significantly associated with FTD [odds ratio (OR)=2.03; p=0.063], but not with AD. MAPT H1 haplotype was associated with AD risk (OR=1.12; p=0.0005). Stratification analysis showed that this association was mainly driven by APOE ε4 noncarriers (OR=1.14; p=0.0025). MAPT H1 was also associated with risk for PD (OR=1.30; p=0.0003) and PSP (OR=3.18; p=8.59 × 10-8) but not FTD. Our results suggest that the MAPT H1 haplotype increases the risk of PD, PSP, and non-APOE ε4 AD., Spanish Ministry of Science and Innovation SAF 2006-10126 (2006–2009) and SAF2010-22329-C02-01 (2011–2013) to P.P and by the UTE project FIMA to P.P. Grants from the Ministry of Science (SAF2010-15558) and CIBERNED. Agust´ın Ruiz is supported by grant PI13/02434 (Acción Estratégica en Salud. Instituto de Salud Carlos III. Ministerio de Economía y Competitividad, Spain). Grant: Consolider (CSD2010-00045).

Published
2015
Full Text
View/download PDF

24. Size and aspect ratio control of Pd2Sn nanorods and their water denitration properties

Author

Catàlisi heterogènia, Departament d'Enginyeria Química, Universitat Rovira i Virgili, ANTOLÍN POZUETA, ANA MARIA, ZhiShan Luo, Maria Ibáñez, Aziz Genc, Alexey Shavel, CONTRERAS IGLESIAS, SANDRA, MEDINA CABELLO, FRANCISCO, Jordi Arbiol, Andreu Cabot, Catàlisi heterogènia, Departament d'Enginyeria Química, Universitat Rovira i Virgili, ANTOLÍN POZUETA, ANA MARIA, ZhiShan Luo, Maria Ibáñez, Aziz Genc, Alexey Shavel, CONTRERAS IGLESIAS, SANDRA, MEDINA CABELLO, FRANCISCO, Jordi Arbiol, and Andreu Cabot

Abstract

Monodisperse Pd2Sn nanorods with tuned size and aspect ratio were prepared by co-reduction of metal salts in the presence of trioctylphosphine, amine, and chloride ions. Asymmetric Pd2Sn nanostructures were achieved by the selective desorption of a surfactant mediated by chlorine ions. A preliminary evaluation of the geometry influence on catalytic properties evidenced Pd2Sn nanorods to have improved catalytic performance. In view of these results, Pd2Sn nanorods were also evaluated for water denitration. © 2015 American Chemical Society.

Published
2015

25. Genetic variation in the tau kinases pathway may contribute to the risk of Alzheimer´s disease

Author

Vázquez Higuera, José Luis, Mateo Fernández, José Ignacio, Sánchez-Juan, Pascual, Rodríguez Rodríguez, Eloy Manuel, Pozueta, Ana, Calero Lara, Miguel, Dobato Ayuso, José Luis, Frank García, Ana, Valdivieso Amate, Fernando, Berciano, José Ángel, Bullido, María Jesús, Combarros Pascual, Onofre, and Universidad de Cantabria

Subjects
Kinases, Alzheimer's disease, Tau, Phosphorylation, Polymorphism
Abstract

Tau abnormal hyperphosphorylation and the formation of neurofibrillary tangles in Alzheimer´s disease (AD) brain is the result of upregulation of tau kinases. In a group of 729 Spanish late-onset AD patients and 670 healthy controls, we examined variations into a set of 20 candidate genes of kinases involved in tau phosphorylation at AD-related sites (PRKACB; CAMK2A; MARK1, 2, 3 and 4; CSNK1D; CDC2; RPS6KB1 and 2; p38α and β; IB1; JNK1, 2 and 3; MEK1 and 2; ERK1 and 2), to address hypotheses of genetic variation that might influence AD risk. There was an increased frequency of RPS6KB2 (intron 2, rs917570) minor allele in patients (50%) versus controls (39%) (OR = 1.52; 95% CI 1.30-1.77; p = 1.24×10−5 Bonferroni corrected), and the CDC2 AGC haplotype derived from SNPs in introns 3 (rs2448347), 5 (rs2456772), and 7 (rs1871447) showed a protective effect against AD in APOE ε4 allele noncarriers (permutation p = 1.0×10-4) with a frequency of 9% in cases and 15% in controls. Common genetic variation in the tau kinases pathway does underlie individual differences in susceptibility to AD.

Published
2011

26. Caspase-1 genetic variation is not associated with Alzheimer's disease risk

Author

Vázquez-Higuera, José Luis, Rodríguez-Rodríguez, Eloy, Sánchez-Juan, Pascual, Mateo, Ignacio, Pozueta, Ana, Martínez-García, Ana, Frank, Ana, Valdivieso Amate, Fernando, Berciano, José, Bullido, María Jesús, Combarros, Onofre, Instituto de Salud Carlos III, Centro Investigación Biomédica en Red Enfermedades Neurodegenerativas (España), and Universidad de Cantabria

Subjects
Male, lcsh:Internal medicine, lcsh:QH426-470, Genotype, Apolipoprotein E4, Interleukin-1beta, Single-nucleotide polymorphism, Disease, Biology, Polymorphism, Single Nucleotide, Sex Factors, Alzheimer Disease, Risk Factors, Genetic variation, medicine, Genetics, Humans, Genetics(clinical), Allele, lcsh:RC31-1245, Genotyping, Genetics (clinical), Aged, Aged, 80 and over, Haplotype, Caspase 1, Age Factors, Genetic Variation, Middle Aged, medicine.disease, lcsh:Genetics, Haplotypes, Immunology, Female, Alzheimer's disease, Research Article
Abstract

4 pages, 2 tables., [Background] Interleukin (IL)-1β is a potent proinflammatory cytokine markedly overexpressed in the brains of patients with Alzheimer's disease (AD), and also involved in development of atherosclerosis and coronary artery disease. Caspase-1 (CASP1), formerly called IL-1β converting enzyme (ICE), mediates the cleavage of the inactive precursor of IL-1β into the biologically active form. CASP1 genetic variation (G+7/in6A, rs501192) has been associated with susceptibility to myocardial infarction and cardiovascular death risk. We examined the contribution of this gene to the susceptibility for AD., [Methods] We examined genetic variations of CASP1 by genotyping haplotype tagging SNPs (htSNPs) (rs501192, rs556205 and rs530537) in a group of 628 Spanish AD cases and 722 controls., [Results] There were no differences in the genotypic, allelic or haplotypic distributions between cases and controls in the overall analysis or after stratification by age, gender or APOE ε4 allele., [Conclusion] Our negative findings in the Spanish population argue against the hypothesis that CASP1 genetic variations are causally related to AD risk., This study was supported by grants from FIS (PI080139) and CIBERNED (CB06/07/ 0037).

Published
2010

27. Genetic variation in the tau protein phosphatase-2A pathway is not associated with Alzheimer's disease risk

Author

Vázquez-Higuera, José L, primary, Mateo, Ignacio, additional, Sánchez-Juan, Pascual, additional, Rodríguez-Rodríguez, Eloy, additional, Pozueta, Ana, additional, Calero, Miguel, additional, Dobato, José L, additional, Frank-García, Ana, additional, Valdivieso, Fernando, additional, Berciano, José, additional, Bullido, Maria J, additional, and Combarros, Onofre, additional

Published
2011
Full Text
View/download PDF

29. Caspase-1 genetic variation is not associated with Alzheimer's disease risk

Author

Vázquez-Higuera, José Luis, primary, Rodríguez-Rodríguez, Eloy, additional, Sánchez-Juan, Pascual, additional, Mateo, Ignacio, additional, Pozueta, Ana, additional, Martínez-García, Ana, additional, Frank, Ana, additional, Valdivieso, Fernando, additional, Berciano, José, additional, Bullido, María J, additional, and Combarros, Onofre, additional

Published
2010
Full Text
View/download PDF

31. Binge Drinking in Young University Students Is Associated with Alterations in Executive Functions Related to Their Starting Age

Author

Fisioterapia, Salas Gomez, Diana, Fernández Gorgojo, Mario, Pozueta, Ana, Díaz Ceballos, Isabel, Lamarain, Maider, Pérez, Carmen, Sánchez Juan, Pascual, Fisioterapia, Salas Gomez, Diana, Fernández Gorgojo, Mario, Pozueta, Ana, Díaz Ceballos, Isabel, Lamarain, Maider, Pérez, Carmen, and Sánchez Juan, Pascual

Abstract

[EN] Our aim was to evaluate whether or not alcohol consumption in the form of binge drinking is associated with alterations of memory and executive functions in a population of university students. At the same time, we have studied the role of potential modulating factors, such as the APOE genotype or physical exercise.University students enrolled in academic year 2013-2014 at Escuelas Universitarias Gimbernat-Cantabria, affiliated with the University of Cantabria, were invited to participate in the study. We gathered sociodemographic data and details regarding the lifestyle of 206 students (mean age 19.55 ± 2.39; 67.5% women). We evaluated memory and executive functions via a series of validated cognitive tests. Participants were classified as binge drinkers (BD) and non-BD. Using Student's t-distribution we studied the association between cognitive tests and BD patterns. Multivariate analyses were carried out via multiple linear regression. 47.6% of the students were found to be BD. The BD differed significantly from the non-BD in their results in the executive functions test TMT B (43.41 ± 13.30 vs 37.40 ± 9.77; p = 0.0003). Adjusting by age, sex, academic records, age at which they started consuming alcohol, cannabis consumption, level of physical activity and other possible modifying variables, the association was statistically significant (p = 0.009). We noticed a statistically significant inverse correlation (Pearson's r2 = -0.192; p = 0.007) between TMT B and starting age of alcohol consumption. Differences were observed in another executive functions test, TMT A, but only in the group of women (19.73±6.1 BD vs 17.78±5.4 non-BD p = 0.05). In spite of the young age of our participants, BD was associated with a lower performance in the executive functions test (TMT B). These deficits were related to the age at which they started drinking alcohol, suggesting an accumulative effect.

32. Physical Activity Is Associated With Better Executive Function in University Students

Author

Fisioterapia, Salas Gomez, Diana, Fernández Gorgojo, Mario, Pozueta, Ana, Diaz Ceballos, Isabel, Lamarain, Maider, Perez, Carmen, Kazimierczak, Martha, Sanchez Juan, Pascual, Fisioterapia, Salas Gomez, Diana, Fernández Gorgojo, Mario, Pozueta, Ana, Diaz Ceballos, Isabel, Lamarain, Maider, Perez, Carmen, Kazimierczak, Martha, and Sanchez Juan, Pascual

Abstract

[EN] Introduction: In recent years, the study of the benefits that physical exercise has on brain health has acquired special relevance. In order to implement exercise as an intervention to protect the brain, it is important to have a more clear idea of its effect in the young population. However, few studies have been carried out on these ages. Objective: The main objective of our study was to evaluate the association between physical activity (PA) with memory and executive function, in university students, analyzing the modulatory effect of sex. Methodology: We collected socio-demographic and life habit information, as well as data on the PA that was carried out during the previous week using the international PAquestionnaire short version (IPAQ-SF) questionnaire in 206 university students (mean age 19.55 ± 2.39; 67.5% women). Memory and executive function were assessed using a comprehensive battery of validate cognitive tests. Univariate and multivariate analyses were performed to correlate PA with cognitive tests scores and to evaluate the potential synergistic role of sex. Results: The main finding was that the total amount of PA correlated positively with several tests that evaluated aspects of executive function, specifically Stroop Colors (Pearson's r = 0.17; p = 0.01) and the Stroop Test Color-Word (Pearson's r = 0.15. p = 0.03). These results were adjusted by a large number of possible confounders and modifying variables in a multivariate analysis, like age, sex, academic record, day of the week, and time at which the test was performed. Additionally, we found out that sex had a synergistic effect with PA on the executive test Trail making test-A (TMTA), and in women, this association was stronger than in men. The more PA women reported, the better they performed, that is to say that they took less time to finalize the TMT-A (interaction term between PA and sex: b = -0.0009; p = 0.014). Conclusion: Our study adds evidence of the benefit of PA in cognition

Catalog

Books, media, physical & digital resources
See catalog results